CA
PTGX icon

Clearstead Advisors’s Protagonist Therapeutics PTGX Stock Holding History

Clearstead Advisors’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.5K Hold
200
– – ﹤0.01% 1740
2026
Q1 		$21.1K Sell
200
-22
-10% -$1.95K ﹤0.01% 1446
2025
Q4 		$19.4K Buy
222
+22
+11% +$1.8K ﹤0.01% 1722
2025
Q3 		$13.3K Buy
200
+90
+82% +$5.12K ﹤0.01% 1823
2025
Q2 		$6.08K Hold
110
– – ﹤0.01% 2053
2025
Q1 		$5.32K Hold
110
– – ﹤0.01% 1736
2024
Q4 		$4.25K Hold
110
– – ﹤0.01% 1744
2024
Q3 		$4.95K Hold
110
– – ﹤0.01% 1711
2024
Q2 		$3.81K Buy
+110
New +$3.22K ﹤0.01% 1728

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Clearstead Advisors's PTGX Position: Q2 2026 in Review

Clearstead Advisors held its Protagonist Therapeutics (PTGX) position steady in Q2 2026 at 200 shares worth $24.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1740.

Clearstead Advisors first reported a position in PTGX in Q2 2024 and has held it in 9 quarters since. 344 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Clearstead Advisors held 200 shares of Protagonist Therapeutics worth $24.5K as of Q2 2026.
  • Clearstead Advisors left its Protagonist Therapeutics share count unchanged in Q2 2026.
  • Protagonist Therapeutics made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #1740 holding.
  • Clearstead Advisors first reported a position in Protagonist Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 344 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.